Drug Profile
Research programme: familial Alzheimer's Disease therapy - Neurotez
Alternative Names: NT1; NT2Latest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Neurotez
- Class Antidementias; Peptides
- Mechanism of Action Cytoplasmic linker protein 170-presenilin 1 interaction inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for preclinical development in Alzheimer's-disease(Prevention) in USA (Parenteral)
- 08 Sep 2020 Preclinical development is ongoing in USA (Neurotez pipeline, September 2020)
- 26 May 2014 Preclinical trials in Alzheimer's disease (prevention, in familial disease) in USA before May 2014 (Parenteral)